Pyxis Oncology doses first subject in Phase 1 trial of ADC PYX-201 for solid tumors

Pyxis Oncology, Inc.

First subject dosed in open-label, dose-escalation Phase 1 trial PYX-201-101; preliminary data expected early 2024.
PYX-201 targets EDB fibronectin, overexpressed in many solid tumors; minimal expression in normal adult tissues.
Trial enrolling patients with NSCLC, HR+ breast, ovarian, thyroid, pancreatic, sarcoma, hepatocellular, kidney cancers.
PYX-201 uses FACT platform licensed from Pfizer (2021) for site-specific conjugation and improved safety profile.
Dosing milestone marks transition of Pyxis Oncology to a clinical-stage company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.